Patients with isolated gonadotrophin deficiency (IGnD) often present a diagnostic problem because of the difficulty in differentiating between it and idiopathic delayed puberty in the prepubertal period.1 2 Referral for endocrine evaluation and treatment is thus often delayed. Although growth of IGnD patients is usually described as normal, 3 4 at the age of puberty there is a slowing of the growth rate. The effect of timing of the initiation of sex hormone replacement therapy is controversial. 5 We carried out a retrospective analysis of the growth pattern of a large group of patients of both sexes with IGnD who have reached final height.
Subjects and methods
We studied 66 patients (50 males, 16 females) with IGnD of idiopathic origin who were followed up from prepuberty to completion of puberty and achievement of final height. They were referred to our clinic for evaluation, of delayed puberty, hypogenitalism, or slowing of growth. Anosmia was diagnosed in 13 males and three females; five of them (four males, one female) belonged to two families. Three Upon referral all patients underwent a comprehensive work up, including routine physical examination and determination of plasma concentrations of sex steroids, gonadotrophins, and prolactin (all assessed by routine radioimmunoassay methods). The diagnosis of IGnD was established by lack of response of plasma luteinising hormone and follicle stimulating hormone to single and repeated gonadotrophin releasing hormone stimulation.8 In the males the response of testosterone to human chorionic gonadotrophin (1500 U given intramuscularly on three alternate days) and in the females the response of oestradiol to human menopausal gonadotrophin (75 U given intramuscularly on three alternative days) were also tested. Data were obtained on parental height. Sex corrected mid-parental height was calculated by adding or subtracting 6 5 cm from the mean parental height (cm) for males and females, respectively. Patients were seen for follow up at intervals of three to six months. Bone age was estimated upon referral and thereafter at intervals of six to 12 months until complete closure of epiphyses of the hand and wrist. Age at termination of puberty and achievement of final height was considered to be that at which growth velocity was less than 1 cm/year and the epiphyses of the hand and wrist were fully ossified.
Puberty was induced as follows: the males received a testosterone depot preparation (Testovirone, Schering), 100 mg intramuscularly monthly and after stage 3 puberty at a dose of 250 mg/month. The females were given conjugated oestrogens (Premarin, Ayerst), 0-625 mg/day and after stage 4 puberty at a dose of 1 25 mg/day, with the addition of medroxyprogesterone acetate (Oragest, Teva), 10 mg/ day for seven days each month, on day 21 of the cycle once vaginal bleeding had occurred. Treatment was maintained throughout the follow up period.
Duration of induced puberty in years and total pubertal growth in cm were calculated by subtracting the age and height respectively at initiation of sex hormone treatment from that at achievement of final height. Also calculated were the growth velocity during the year before initiation of treatment (GVO) and that during the first year of treatment (GV,). Standing height was expressed in actual measurements (cm) and in standard deviation score (HtSDS), using
Tanner's SD tables.9 Parental HtSDS was calculated from the sex corrected mid-parental height by the same method, using the highest age available in the SD tables. Bone maturation index was calculated from the pretreatment and treatment periods using the equation A bone age: A chronological age.
Statistical analysis of the results was performed using the paired or unpaired Student's t test with two tailed significance levels for 
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was also higher in the males referred at a younger age than those referred beyond age 16 (p<0 05) and than in the females (p<005). The duration of induced puberty was longest in the younger male group (p<O0OOl), similar to the normal pattern of puberty in males, and shortest in the females (table 3) . The mean total pubertal growth was significantly greater in the younger males than in the older males and in the females (p<O0OOOl) and lowest in group 2 of the males. The bone maturation index increased significandy (p<OOl) in all patients during the treatment period as compared with their pretreatment values (table 3) . The mean final HtSDS was close to the mean normal range in all groups (table 3) and significantly higher than at initiation of treatment (p<O0OOl). The mean final height was also higher than the mean midparental HtSDS in all groups (p<005). There was no significant difference in the mean final HtSDS between the younger and older male groups.
The correladtion regression analysis revealed that the most significant factor affecting the induced pubertal growth in both sexes was the bone age at initiation of sex hormone treatment (table 4) . It did not, however, affect the final height. The height of patients, both at initiation of sex hormone treatment and upon achievement of final height, was found to be significantly correlated with the mid-parental height (all patients r=062, p=0 03 and males: r=0 64, p=0-02; females: r=0-67, p=0-01,respectively).
Discussion
Patients with IGnD provide a clinical model for the evaluation of the role of gonadotrophins in prepubertal growth and of sex hormones in achieving maximal final height. It has been well documented that a close relationship exists between puberty and growth, and that sexual development, whether spontaneous or induced, is associated with a rise in plasma growth hormone and insulin-like growth factor-I (IGF-I).11-4 The rise in IGF-I concentrations during puberty is mediated by the gradual increase in growth hormone secretion induced by the rising concentration of sex hormones. The relatively short stature of our IGnD patients upon referral before initiation of sex hormone treatment may reflect a low pituitary growth hormone output and a low plasma IGF-I concentration due to insufficient secretion of sex hormones during the pretreatment period. ''7 Our review of this large series of both sexes showed that IGnD tends to be diagnosed at an earlier age in boys than in girls. This is due to the fact that hypogonadism and hypogenitalism are more readily apparent in the male. This difference led to earlier initiation of sex hormone treatment in some of the boys (group 1). This study confirms previous reports that IGnD patients of both sexes achieve a normal final height.3' In the males institution of treatment with a low dose (100 mg/month) of a depot preparation of testosterone and progressively increasing the dose up to 250 mg/ month resulted in a comparable final height whether treatment was initiated at an earlier or later age. However, the earlier initiation of treatment in the boys in group 1 resulted in a longer period until ossification of the epiphyses had been completed and in a greater height gain during the period of induced puberty, as compared with the boys in group 2. The latter were, however, taller upon initiation of treatment, which compensated for the lesser growth during the period of induced puberty and the result was a similar final height in both these groups. These results are in agreement with those of Bourguignon who compared the effect of sex hormone induced puberty on final height in hypopituitary patients with growth hormone and gonadotrophin deficiency with that in hypopituitary patients with spontaneous occurrence of puberty.' 18 The females with IGnD showed a growth pattern similar to that of the group 2 males. In both the females and the group 2 males chronological age and bone age at referral and initiation of treatment were relatively greater than in the males of group 1.
The importance of the genetic influence on growth is reflected in the significant positive correlation between the height of the patients, both pretreatment and final height, and the sex corrected mid-parental height. Most of the patients with IGnD, and particularly the females, achieved a significantly taller final height than the sex corrected mid-parental height. This can be explained partly by the effect of the secular trend of the general population. Pescovitz in a review of the endocrinology of the pubertal growth spurt, suggests that in IGnD the absence of gonadal sex steroids results in a delayed pubertal growth spurt and probably a small but significant increase in final adult height. 9 The fact that at initiation of sex hormone treatment the height of patients was relatively short in comparison with the midparental height and that there was a height gain of 1 SD during the period of treatment supports the suggestion that with low to moderate doses of sex hormones, such as used in the present study, there is initially more effect on linear growth than on bone maturation.20 21 Of interest among the findings in this study is the fact that plasma testosterone response to human chorionic gonadotrophin stimulation in the males with IGnD was significantly lower than in normal boys at comparable pubertal stages, indicating the usefulness of this test to distinguish between 'simple' delayed puberty and permanent IGnD states in males.
In conclusion, the results of this study indicate that IGnD patients achieve normal final height irrespective of the timing of initiation of sex hormone treatment. It is therefore suggested that the timing of sex hormone replacement treatment should be decided on the basis of psychosocial determinants.
